2008 Clinical Practice Guidelines - Canadian Diabetes Association

12. Moy CS, Songer TJ, LaPorte RE, et al. Insulin-dependent diabetes
mellitus, physical activity, and death. Am J Epidemiol.
1993;137:74-81.
13. Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes
mellitus on mortality from all causes and coronary heart
disease in women: 20 years of follow-up. Arch Intern Med.
2001;161:1717-1723.
14. Wei M, Gibbons LW, Kampert JB, et al. Low cardiorespiratory
fitness and physical inactivity as predictors of mortality in
men with type 2 diabetes. Ann Intern Med. 2000;132:605-611.
15. Warburton DE, Nichol CW, Bredin SS. Health benefits of
physical activity: the evidence. CMAJ. 2006;174:801-809.
16. Church TS, Cheng YJ, Earnest CP, et al. Exercise capacity and
body composition as predictors of mortality among men with
diabetes. Diabetes Care. 2004;27:83-88.
17. Pyörälä K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering
with simvastatin improves prognosis of diabetic patients with
coronary heart disease. A subgroup analysis of the Scandinavian
Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-620.
18. Sacks FM, Pfeffer MA, Moye LA, et al.The effect of pravastatin
on coronary events after myocardial infarction in patients with
average cholesterol levels. Cholesterol and Recurrent Events
Trial investigators. N Engl J Med. 1996;335:1001-1009.
19. Prevention of cardiovascular events and death with pravastatin
in patients with coronary heart disease and a broad range of
initial cholesterol levels. The Long-term Intervention with
Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl
J Med. 1998;339:1349-1357.
20. Collins R, Armitage J, Parish S, et al; Heart Protection Study
Collaborative Group. MRC/BHF Heart Protection Study of
cholesterol-lowering with simvastatin in 5963 people with diabetes:
a randomised placebo-controlled trial. Lancet. 2003;361:
2005-2016.
21. Heart Protection Study Collaborative Group. MRC/BHF
Heart Protection Study of cholesterol lowering with simvastatin
in 20,536 high-risk individuals: a randomised placebocontrolled
trial. Lancet. 2002;360:7-22.
22. Colhoun HM, Betteridge DJ, Durrington PN, et al; CARDS
Investigators. Primary prevention of cardiovascular disease
with atorvastatin in type 2 diabetes in the Collaborative
Atorvastatin Diabetes Study (CARDS): multicentre randomised
placebo-controlled trial. Lancet. 2004;364:685-696.
23. LaRosa JC, Grundy SM, Waters DD, et al; Treating to New
Targets (TNT) Investigators. Intensive lipid lowering with
atorvastatin in patients with stable coronary disease. N Engl J
Med. 2005;352:1425-1435.
24. Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL
cholesterol substantially below currently recommended levels
in patients with coronary heart disease and diabetes: the
Treating to New Targets (TNT) study. Diabetes Care. 2006;29:
1220-1226.
25. Evans JM, Wang J, Morris AD. Comparison of cardiovascular
risk between patients with type 2 diabetes and those who had
had a myocardial infarction: cross sectional and cohort studies.
BMJ. 2002;324:939-942.
26. Sever PS, Poulter NR, Dalhof B, et al. Reduction in cardiovascular
events with atorvastatin in 2532 patients with type 2 diabetes.
Anglo-Scandinavian Cardiac Outcomes Trial–lipid-lowering arm
(ASCOT-LLA). Diabetes Care. 2005;28:1151-1157.
27. Knopp RH, D’emden M, Smilde SJ, et al. Efficacy and safety
of atorvastatin in the prevention of cardiovascular end points in
subjects with type 2 diabetes: the Atorvastatin Study for
Prevention of Coronary Heart Disease Endpoints in noninsulin-dependent
diabetes mellitus (ASPEN). Diabetes Care.
2006;29:1478-1485.
28. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment
Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering
treatment: prospective meta-analysis of data
from 90,056 participants in 14 randomised trials of statins.
Lancet. 2005;366:1267-1278.
29. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance
is a risk factor for cardiovascular disease, but not
impaired fasting glucose. Diabetes Care. 1999;22:920-924.
30. Girman CJ, Rhodes T, Mercuri M, et al; 4S Group and the
AFCAPS/TexCAPS Research Group.The metabolic syndrome
and risk of major coronary events in the Scandinavian
Simvastatin Survival Study (4S) and the Air Force/Texas
Coronary Atherosclerosis Prevention Study (AFCAPS/
TexCAPS). Am J Cardiol. 2004;93:136-141.
31. Genest J, Frohlich J, Fodor G, et al; Working Group on
Hypercholesterolemia and Other Dyslipidemias. Recommendations
for the management of dyslipidemia and the prevention
of cardiovascular disease: summary of the 2003 update.
CMAJ. 2003;169:921-924.
32. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin
on lipid and lipoprotein levels and glycemic control in patients
with diabetes and peripheral arterial disease: the ADMIT
study: a randomized trial. Arterial Disease Multiple
Intervention Trial. JAMA. 2000;284:1263-1270.
33. Grundy SM, Vega GL, McGovern ME, et al; Diabetes
Multicenter Research Group. Efficacy, safety, and tolerability
of once-daily niacin for the treatment of dyslipidemia associated
with type 2 diabetes: results of the assessment of diabetes
control and evaluation of the efficacy of niaspan trial. Arch
Intern Med. 2002;162:1568-1576.
34. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin,
antioxidant vitamins, or the combination for the prevention of
coronary disease. N Engl J Med. 2001;345:1583-1592.
35. Taylor AJ, Sullenburger LE, Lee HJ, et al. Arterial Biology for
the Investigation of the Treatment Effects of Reducing
Cholesterol (ARBITER) 2: a double-blind, placebo-controlled
study of extended-release niacin on atherosclerosis progression
in secondary prevention patients treated with statins.
Circulation. 2004;110:3512-3517.
36. Griffin BA, Freeman DJ,Tait GW, et al. Role of plasma triglyceride
in the regulation of plasma low density lipoprotein (LDL)
subfractions: relative contribution of small, dense LDL to coronary
heart disease risk. Atherosclerosis. 1994;106:241-253.
S113
COMPLICATIONS AND COMORBIDITIES